发明名称 |
Modalities for the treatment of degenerative diseases of the retina |
摘要 |
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. |
申请公布号 |
US9080150(B2) |
申请公布日期 |
2015.07.14 |
申请号 |
US201213477763 |
申请日期 |
2012.05.22 |
申请人 |
Ocata Therapeutics, Inc. |
发明人 |
Klimanskaya Irina V.;Lanza Robert |
分类号 |
A61K35/12;C12N5/0793;A61K35/44;A61K49/00;A61P27/02;C12N5/071;C12N5/079;A61K35/30;A61K35/36;A61K35/545 |
主分类号 |
A61K35/12 |
代理机构 |
Wolf, Greenfield & Sacks, P.C. |
代理人 |
Wolf, Greenfield & Sacks, P.C. |
主权项 |
1. A method of producing a human RPE cell preparation suitable for transplantation into the eye of a human patient in need thereof, comprising:
(a) differentiating in vitro human pluripotent cells that express Oct-4, alkaline phosphatase, SSEA-3, SSEA-4, TRA-I-60, and TRA-I-81 under conditions that do not maintain the undifferentiated state of the human pluripotent cells to obtain a heterogeneous population of human cells including pigmented cells comprising brown pigment dispersed in their cytoplasm; (b) culturing the pigmented cells to form a monolayer of RPE cells having a cobblestone, polygonal, epithelial-like appearance that express RPE65 and bestrophin, and (c) isolating and purifying said RPE cells. |
地址 |
Marlborough MA US |